New commitments from governments, international organizations and the private sector supported an integrated approach to ending the epidemic, supporting unprecedented scale, scope and speed response – through Access to COVID-19 Tools Accelerator – Pandemic Claims over 1 million lives.
Recent commitments at a glance:
- United Kingdom £ 571m (US $ 732m) for the COVAX column of access to the COVID-19 Tools- (ACT) accelerator, of which £ 500m (US $ 641m) is to support low- and middle-income countries. This includes a commitment to match £ 1 for every US $ 4 made by others up to £ 250m (US $ 321m).
- Canada CAD 440m (US $ 332m) for the COVAX column of the ACT-accelerator, of which CAD 220 (US $ 166m) is intended to support low- and middle-income countries
- Germany EUR 100m (US $ 117m) for the COVAX column of the ACT-accelerator, which is to support all low and middle income countries
- Sweden US $ 10m for the COVAX column of ACT-Accelerator, which is to support all low and middle income countries
- world Bank US $ 12 billion to support developing countries to purchase COVID-19 vaccines as soon as they become available (to be ratified by their shareholders)
- Alliance of 16 pharmaceutical companies And this Bill & Melinda Gates Foundation Signed an agreement to collaborate on vaccine manufacturing and increase production
The United Nations and its partners today welcomed a grand demonstration of solidarity, as governments, the private sector, civil society, and international organizations have supported access to the COVID-19 tool – (ACT) with international partners by the World Health Organization Accelerator initiative launched.
Today, approximately US $ 1 billion in new funding is committed to the world’s most comprehensive multilateral end-to-end initiative for the devastating COVID-19 pandemic.
The act-accelerator, which was co-launched just five months ago by the World Health Organization, the European Commission, France, and the Bill & Melinda Gates Foundation, is expected to realize an additional US $ 2 billion vaccine dose, to realize its goals of producing 245. $ 35 billion is required. Lacquer treatment and 500 million trials. New commitments to the initiative are welcome and will be stimulated to raise further funds to continue the ground work of the ACT-accelerator.
Most immediately, ACT-Accelerator requires US $ 15 billion to support immediate capacity building for research and development, manufacturing, procurement and distribution systems by the end of the year.
Organizing a high-level program in the 75th session of the United Nations General Assembly to immediately mobilize support for ACT-acceleration, General Secretary Antonio Guterres Praising the “extraordinary international effort to address the human crisis like no other in our lifetime”, said more efforts should be made to “deepen” the remarkable progress so far.
“It is in each country’s national and economic self-interest to work together to expand wider access to tests and treatments, and to support a vaccine as a global public -” people’s vaccine ” Available to everyone and affordable everywhere. “
“ACT-Accelerator – including its COVAX facility – is the vehicle to get us there. Investing in the ACT-accelerator will accelerate every recovery in the country, ”said Mr. Guterres, who co-hosted the event with United Kingdom Foreign Secretary Dominic Rabb, South Africa’s Health Minister Zweli Mkhize and the Director General of the World Health Organization Of. Dr. Tedros Adnom Ghebreyasus.
Unprecedented global cooperation
ACT-Accelerator, which was launched just five months ago, is an unprecedented global collaboration of the world’s top international health organizations to accelerate the development, production and equitable delivery of COVID-19 trials, treatments and vaccines. doing work.
“We have a duty to ensure that COVID-19 vaccines, treatments and tests are all available – stopping the global spread of the epidemic protects the British people and will bring humanity on the road to recovery. Cooperation through ACT-Accelerator is important to promote development, production and access for all countries UK Foreign Secretary Dominic Raab.
The United Kingdom has recently committed £ 571m (approximately US $ 732m) for COVAX. This includes up to £ 500m for the Gavi Advanced Market Commitment for COVID-19 (COVAX AMC) vaccines – a financing tool that encourages vaccine manufacturers to produce enough COVID-19 vaccines to ensure access to developing countries is.
Today, the UK Foreign Secretary called for more support, saying that this £ 500m commitment included £ 1 (IS $ 1.29), which for every US $ 4 was up to £ 250m (about US $ 321m) for others. Is committed to.
Germany, Canada and Sweden have also made new commitments for Kovacs AMC worth Euro 100 million, CAD $ 220 million and US $ 10 million respectively. These are eligible for matching commitments with today’s UK.
“Science is giving us new tests, medical science and solutions in the form of an expectation — a vaccine. But science and solutions will be ineffective without solidarity, ”said Dr. Tedros Adnom Ghebreyas, WHO Director General.
“I am grateful for the generous financial commitments made today, but we still have a significant wealth gap. Fully financing the ACT accelerator will help control the epidemic, restore confidence and encourage global recovery. Frankly, this is not a financial challenge, it is a test of solidarity. This is a moment to say no to nationalism and to say yes to our shared humanity. Because after all, the ACT accelerator is not just giving vaccines, diagnostics and medical science. It is something more important – hope.
While working towards a global solution, we should face this health crisis as a global challenge with solidarity and cooperation. We must generate key trials, treatments and vaccines that we all need, and ensure that they are evenly distributed to those who need them most, regardless of where they live and whether they want them. Whether the country is prosperous or not, ”he said. South african Health Minister Jewelie Makhise, Large sections of the population, especially in developing countries, remain “vulnerable and marginalized during this epidemic”.
Today’s event highlighted the substantial results achieved by access to the COVID-19 Tool Accelerator initiative since its launch: the availability of 120 million inexpensive and high-quality rapid trials for low and middle-income countries; A breakthrough in the trial, and a rapid rollout of, dexamethasone – the only drug found to make a significant difference to the patient’s mortality; Building the COVAX facility – a global mechanism to ensure access to COVID-19 vaccine incomes regardless of 168 economies, and the largest and most diverse vaccine portfolio in the world, with nine candidate vaccines under evaluation. There are eight clinical trials.
In another significant show of support, a coalition of 16 pharmaceutical companies and the Bill & Melinda Gates Foundation signed an agreement to collaborate on vaccine manufacturing and to increase production at an unprecedented pace, ensuring that approved vaccines are more comprehensive Are as accessible and delivered as quickly as possible.
Bill Gates, co-chairman of the Bill & Melinda Gates Foundation He said, “One thing that studies the history of epidemics is that when they speak of selfishness and altruism, they create a surprising momentum. Epidemics are rare cases where a country’s instinct to help itself to others Is tightly coupled with their instinct to do it. Self-interested things and philanthropic things – make sure vaccines have access to poor nations – one and the same. “
“Many countries, most recently the United Kingdom and Canada, are good models for what other wealthy countries should do. They have donated enough funds for COVAX, ACT-Accelerator’s Vaccine Pillar, to purchase, perhaps, Millions of vaccine supplements for poor countries. But more will be required and I hope the rich countries will remain generous. ”
The World Bank unveiled plans this week for a significant financial commitment to support developing countries to purchase COVID-19 vaccines that are available for this week.
World Bank President David Malpas After plans were confirmed by stakeholders, “with up to US $ 12 billion in finance available, will be a game changer because once a safe and effective vaccine is available, it allows people to resume their lives with confidence Will allow to do. “
Investment in global recovery
The case of ACT-accelerator investment demonstrates the considerable economic benefits of collectively accelerating the development and deployment of devices to reduce the risk of severe COVID-19 disease globally. Prior to UNGA 2020, ACT-Accelerator has raised $ 3 billion from the US $ 38 billion requirement. More details can be found in the case of act-accelerator investment.
The economic rationale for investing in an approach that accelerates the end of the COVID-19 crisis is clear. Fully funding to help reduce the duration of the crisis must return this investment in less than 36 hours if global mobility and trade alone is restored.
Notes to editors
The COVID-19 device is a proven, up-and-running global collaboration to accelerate access to ACT-accelerators, COVID-19 testing, treatment and vaccine development, production, and equitable access. It was launched in March 2020 in response to a call from G20 leaders and in April 2020 by the WHO, European Commission, France and The Bill and Melinda Gates Foundation.
The act-accelerator is not a decision-making body or a new organization, it serves to intensify collaborative efforts between existing organizations to end the epidemic. It is a framework for collaboration that is designed to bring key players around the table with the goal of ending the epidemic as quickly as possible through accelerated development, uniform allocation, and delivery of trials, treatments and vaccines. , Thereby restoring health systems and societies and economies in the near future.
It draws on the experience of leading global health organizations that are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to defeat COVID-19 and ensure access to all the means necessary to work with an unprecedented level of partnership to achieve it.
The Act-Accelerator consists of four pillars: diagnosis, medicine, vaccines and strengthening the health system.
Diagnostic Pillar, called by co. Global Fund And FIND, Focused on bringing 2-3 high-quality rapid tests to market, training 10 000 healthcare professionals in 50 countries and setting up trials for 500 million people in low- and middle-income countries by mid-2021 .
Medical pillar is headed Unitaid And this Welcome Trust. COVID-19 can play a therapeutic role in all stages of the disease: to prevent infection; Suppressing symptoms and spreading the infection to others; Treating or preventing symptoms; As a life-saving treatment for severe symptoms; And as a treatment that can accelerate recovery. The objective is to develop, manufacture and deliver 245 million treatments over the next 12 months, which will help COVID-19 victims recover from the disease.
TK Pillar, called by CEPI, Gavi And WHO, Is accelerating the search for an effective vaccine for all countries. At the same time, it is supporting the creation of manufacturing capabilities, and purchasing supplies, ahead of time so that by the end of 2021, 2 billion doses can be substantially distributed.
Led health system connector column world Bank And this Global Fund, Is working to ensure that these devices can reach the people who need them.
Cross-cutting all of these is a workstream on access and allocation hosted by World Health Organization.
for more information please visit:
WHO ACT-Accelerator website: who.int/initiatives/act-accelerator
Status report and plan: bit.ly/ACTAcceleratorStatusReport
Economic Investment Case: bit.ly/ACTAcceleratorInvestmentCase
UN COVID-19 Response Portal: un.org/en/coronavirus
Archived video of the event is available on UN Web TV